76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Arcutis Biotherapeutics Inc
Open
SectorHealthcare
14.17 5.04
Overview
Share price change
24h
Min
13.56
Max
14.51
Income | -14M -25M |
|---|---|
Sales | -5.5M 66M |
EPS | -0.2 |
Profit margin | -38.059 |
Employees | 342 |
EBITDA | -20M -25M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +59.31% upside |
Next Earnings | 13 Aug 2025 |
|---|
Market Cap | -210M 1.6B |
|---|---|
Previous open | 9.13 |
Previous close | 14.17 |
News Sentiment
By Acuity
50%
50%
167 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Arcutis Biotherapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Arcutis Biotherapeutics Inc Forecast
Price Target
By TipRanks
59.31% upside
12 Months Forecast
Average 21.14 USD 59.31%
High 29 USD
Low 19 USD
Based on 7 Wall Street analysts offering 12 month price targets forArcutis Biotherapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
167 / 380 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
